Wound Management Technologies, Inc. (WNDM) is a rapidly growing provider of first-in-class specialty medical products, advanced biotechnology solutions and technology applications to secure healthcare data delivery and messaging. The company is dedicated to creating and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Our mission is to deliver life-enhancing therapeutics and biopharmaceuticals via high-quality clinical research, product development and demand side marketing initiatives. Wound Management has extended its biotech footprint in healthcare with the recent acquisition of Secure eHealth, LLC a provider of secure health data and messaging alert solutions which provide a collaboration platform between health providers, healthcare insurers, ancillary services and patients.

Wound Care Innovations, LLC a wholly owned subsidiary of Wound Management Technologies, Inc., brings to the medical wound care arena a unique and dynamic mix of expertise, products, applications, delivery, and service. Clinical biotech research has shown that collagen is much more than just the most prevalent component of skin. Research documents that collagen offers structural support, and has the capabilities to actively assist in the body's wound healing processes - especially in diabetes wound care. Collagen has been proven to trigger every critical process involved in the body's healing of diabetes wounds and help establish balance in the wound bed. The patented, activated form of collagen in CellerateRX ® products is the only one on the market that provides the inherent active properties of collagen to the body immediately.